Unknown

Dataset Information

0

Structure-Based Design of a Small Molecule CD4-Antagonist with Broad Spectrum Anti-HIV-1 Activity.


ABSTRACT: Earlier we reported the discovery and design of NBD-556 and their analogs which demonstrated their potential as HIV-1 entry inhibitors. However, progress in developing these inhibitors has been stymied by their CD4-agonist properties, an unfavorable trait for use as drug. Here, we demonstrate the successful conversion of a full CD4-agonist (NBD-556) through a partial CD4-agonist (NBD-09027), to a full CD4-antagonist (NBD-11021) by structure-based modification of the critical oxalamide midregion, previously thought to be intolerant of modification. NBD-11021 showed unprecedented neutralization breath for this class of inhibitors, with pan-neutralization against a panel of 56 Env-pseudotyped HIV-1 representing diverse subtypes of clinical isolates (IC50 as low as 270 nM). The cocrystal structure of NBD-11021 complexed to a monomeric HIV-1 gp120 core revealed its detail binding characteristics. The study is expected to provide a framework for further development of NBD series as HIV-1 entry inhibitors for clinical application against AIDS.

SUBMITTER: Curreli F 

PROVIDER: S-EPMC4676410 | biostudies-literature | 2015 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Structure-Based Design of a Small Molecule CD4-Antagonist with Broad Spectrum Anti-HIV-1 Activity.

Curreli Francesca F   Kwon Young Do YD   Zhang Hongtao H   Scacalossi Daniel D   Belov Dmitry S DS   Tikhonov Artur A AA   Andreev Ivan A IA   Altieri Andrea A   Kurkin Alexander V AV   Kwong Peter D PD   Debnath Asim K AK  

Journal of medicinal chemistry 20150828 17


Earlier we reported the discovery and design of NBD-556 and their analogs which demonstrated their potential as HIV-1 entry inhibitors. However, progress in developing these inhibitors has been stymied by their CD4-agonist properties, an unfavorable trait for use as drug. Here, we demonstrate the successful conversion of a full CD4-agonist (NBD-556) through a partial CD4-agonist (NBD-09027), to a full CD4-antagonist (NBD-11021) by structure-based modification of the critical oxalamide midregion,  ...[more]

Similar Datasets

| S-EPMC5079829 | biostudies-literature
| S-EPMC3993944 | biostudies-literature
| S-EPMC8528216 | biostudies-literature
| S-EPMC4789667 | biostudies-literature
| S-EPMC3690859 | biostudies-other
| S-EPMC6591293 | biostudies-literature
| S-EPMC1877983 | biostudies-literature
| S-EPMC6668673 | biostudies-literature
| S-EPMC3376652 | biostudies-literature
| S-EPMC5776682 | biostudies-literature